Stephanie T. Weiss

Stephanie T. Weiss

Auto-generated profile, based on publicly available information

Stephanie T. Weiss

Translational Addiction Medicine Branch, Intramural Research Program, National Institute On Drug Abuse, National Institutes of Health, Baltimore, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
SWStephanie T. Weiss
Stephanie T. Weiss
HDHeather E. Douglas
Heather E. Douglas
Introduction: Some opioid use disorder (OUD) patients attempt to self-treat using herbal remedies such as kratom. However, kratom use itself can paradoxically cause physical dependence and OUD. Currently, there are no guidelines for treating patients with OUD stemming from kratom use. Our empirically-based hypothesis was that there would be a correlation between the amount of kratom used and the amount of buprenorphine-naloxone required for opioid agonist therapy. Methods: This study includes a systematic review assessing treatment of kratom-dependent patients with buprenorphine-naloxone; a case series of our kratom-dependent patients; calculation of the correlation between the kratom dose and the buprenorphine-naloxone dose required to treat kratom-associated OUD; and our proposed starting doses for using buprenorphine-naloxone to treat kratom OUD. Results: The OVID MEDLINE (1946–2020) database was searched using the terms “kratom,” “buprenorphine,” and “case report.” This search yielded 3 relevant cases of patients having kratom OUD who were treated with buprenorphine-naloxone with the amounts of all substances reported. Review of the bibliographies, citing articles, and Google Scholar turned up three additional cases, yielding 6 literature cases that were analyzed. We also analyzed 2 patients from our clinic, giving a total of 8 patients included in the Pearson correlation coefficient calculation. We found a strong correlation of 0.84 between these variables, consistent with our hypothesis. Conclusions: Based on our analysis, patients using 40 g/d could be initiated with 12/3 mg-16/4 mg of buprenorphine-naloxone/day.

20 May 2024 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
JRJeffrey Michael Rogers
Jeffrey Michael Rogers
SWStephanie T. Weiss
Stephanie T. Weiss
DEDavid H. Epstein
David H. Epstein
Oliver GrundmannOliver Grundmann
Oliver Grundmann
KHKatherine Hill
Katherine Hill
KSKirsten E. Smith
Kirsten E. Smith

24 November 2020 in The American Journal of Drug and Alcohol Abuse
Verified
Journal Article
Closed access
CDChristian Davidson
Christian Davidson
DCDazhe Cao
Dazhe Cao
TKTaylore King
Taylore King
SWStephanie T. Weiss
Stephanie T. Weiss
SWSunun Wongvisavakorn
Sunun Wongvisavakorn
SSSahaphume Srisuma
Sahaphume Srisuma
Background: Interest in the Southeast Asian natural remedy kratom has increased in Western countries recently, along with increasing concern over its potential toxic effects. Objective: To describe and compare demographics, common co-exposure substances, clinical effects, treatments, and medical outcomes of kratom “abuse” exposures in the United States (US) and Thailand. Methods: This is a retrospective analysis of kratom “abuse” exposures, defined as use when attempting to gain a psychotropic effect, reported to the National Poison Data System (NPDS) in the US and the Ramathibodi Poison Center (RPC) in Thailand from 2010 to 2017. Multivariate analysis identified risk factors for severe medical outcomes, defined as both ICU admissions and death. Results: Nine-hundred-twenty-eight cases were included (760 from NPDS and 168 from RPC). A greater proportion of cases involved co-exposures in Thailand (64.8% versus 37.4%; odds ratio [OR] = 3.10, 95% confidence interval [CI] = 2.15–4.47, p < .01). Both countries had a similar prevalence of opioid and benzodiazepine co-ingestions, but the US had more co-ingestions with other sedatives (4.6% versus 0%, OR = 0, 95% CI = 0–0.47, p < .01). Common clinical effects included tachycardia (30.4%), agitation/irritability (26.2%), and drowsiness/lethargy (21.1%). Six deaths occurred, including one single-substance exposure in the US, three multiple-substance exposures in the US, and two multiple-substance exposures in Thailand. IV fluid administration was provided more frequently in the US (OR = 18.82, 95% CI = 5.85–60.56, p < .01). Conclusions: Despite lower frequencies of co-ingestants overall, US kratom abuse exposures yielded greater clinical severity. This disparity may be attributable to differences in the products labeled “kratom,” greater sedative co-exposures in the US, and/or differences in population genetics or use patterns.

13 August 2024 in Current Psychiatry Reports
Verified
Journal Article
Open access
PDF file
KSKirsten E. Smith
Kirsten E. Smith
DEDavid H. Epstein
David H. Epstein
SWStephanie T. Weiss
Stephanie T. Weiss
Purpose of Review: We apply the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria for substance use disorders (SUDs) to the herbal product kratom. Similarities and differences between kratom use disorder (KUD) and other SUDs are explored, along with assessment, diagnostic, and therapeutic recommendations for KUD. Recent Findings: Literature reports of “kratom addiction” or KUD rarely specify the criteria by which patients were diagnosed. Individuals meeting DSM-5 KUD criteria typically do so via tolerance and withdrawal, using more than intended, and craving, not functional or ​psychosocial disruption, which occur rarely. Most clinicians who use medication to treat patients with isolated KUD select buprenorphine formulations, although there are no controlled studies showing that buprenorphine is safe or efficacious in this patient population. Summary: Diagnosis and treatment decisions for KUD should be systematic. We propose an algorithm that takes into consideration whether KUD occurs with comorbid opioid use disorder.

7 September 2022 in Clinical Toxicology
Verified
Journal Article
Closed access
SWStephanie T. Weiss
Stephanie T. Weiss
LVLaura J. Veach
Laura J. Veach
WMWilliam McGill
William McGill
JBJeffrey Brent
Jeffrey Brent
Trauma centers are required to screen patients for alcohol use, and if necessary, intervene and refer to treatment (SBIRT). Similar screening for illicit drug use is recommended but not required. U...

4 February 2023 in Current Addiction Reports
Verified
Journal Article
Closed access
PDF file
SWStephanie T. Weiss
Stephanie T. Weiss
JBJeffrey Brent
Jeffrey Brent